222 related articles for article (PubMed ID: 37604067)
21. Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines.
Newlands C; Currie R; Memon A; Whitaker S; Woolford T
J Laryngol Otol; 2016 May; 130(S2):S125-S132. PubMed ID: 27841126
[TBL] [Abstract][Full Text] [Related]
22. Noninvasive monitoring of basal cell carcinomas treated with systemic hedgehog inhibitors: pseudocysts as a sign of tumor regression.
Maier T; Kulichova D; Ruzicka T; Berking C
J Am Acad Dermatol; 2014 Oct; 71(4):725-30. PubMed ID: 24928708
[TBL] [Abstract][Full Text] [Related]
23. Current diagnosis and treatment of basal cell carcinoma.
Alter M; Hillen U; Leiter U; Sachse M; Gutzmer R
J Dtsch Dermatol Ges; 2015 Sep; 13(9):863-74; quiz 875. PubMed ID: 26882375
[TBL] [Abstract][Full Text] [Related]
24. Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature.
Proietti I; Filippi L; Tolino E; Bernardini N; Svara F; Trovato F; Di Cristofano C; Petrozza V; Bagni O; Vizzaccaro A; Skroza N; Potenza C
Biomedicines; 2023 Oct; 11(11):. PubMed ID: 38001904
[No Abstract] [Full Text] [Related]
25. Sonidegib for the Treatment of Advanced Basal Cell Carcinoma.
Brancaccio G; Pea F; Moscarella E; Argenziano G
Front Oncol; 2020; 10():582866. PubMed ID: 33194718
[TBL] [Abstract][Full Text] [Related]
26. Identifying patients at risk for recurrent or advanced BCC.
Hamid O; Goldenberg G
J Drugs Dermatol; 2013 Nov; 12(11):1246-52; quiz 1253-4. PubMed ID: 24196332
[TBL] [Abstract][Full Text] [Related]
27. Current landscape for treatment of advanced basal cell carcinoma.
Foley P
Australas J Dermatol; 2015 Mar; 56 Suppl 1():1-7. PubMed ID: 25715811
[TBL] [Abstract][Full Text] [Related]
28. Cemiplimab for locally advanced and metastatic basal cell carcinoma.
Damsin T; Lebas E; Marchal N; Rorive A; Nikkels AF
Expert Rev Anticancer Ther; 2022 Mar; 22(3):243-248. PubMed ID: 35175882
[TBL] [Abstract][Full Text] [Related]
29. Advanced basal cell carcinoma: What dermatologists need to know about treatment.
Wilson M; Johnson RP; Senft SC; Pan EY; Krakowski AC
J Am Acad Dermatol; 2022 Jun; 86(6S):S14-S24. PubMed ID: 35577406
[TBL] [Abstract][Full Text] [Related]
30. Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
Bichakjian CK; Olencki T; Aasi SZ; Alam M; Andersen JS; Berg D; Bowen GM; Cheney RT; Daniels GA; Glass LF; Grekin RC; Grossman K; Higgins SA; Ho AL; Lewis KD; Lydiatt DD; Nehal KS; Nghiem P; Olsen EA; Schmults CD; Sekulic A; Shaha AR; Thorstad WL; Tuli M; Urist MM; Wang TS; Wong SL; Zic JA; Hoffmann KG; Engh A
J Natl Compr Canc Netw; 2016 May; 14(5):574-97. PubMed ID: 27160235
[TBL] [Abstract][Full Text] [Related]
31. Management of basal cell carcinoma by surveyed dermatologists in Scotland.
Gudi V; Ormerod AD; Dawn G; Green C; MacKie RM; Douglas WS; Gupta G;
Clin Exp Dermatol; 2006 Sep; 31(5):648-52. PubMed ID: 16901303
[TBL] [Abstract][Full Text] [Related]
32. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.
Dummer R; Guminksi A; Gutzmer R; Lear JT; Lewis KD; Chang ALS; Combemale P; Dirix L; Kaatz M; Kudchadkar R; Loquai C; Plummer R; Schulze HJ; Stratigos AJ; Trefzer U; Squittieri N; Migden MR
Br J Dermatol; 2020 Jun; 182(6):1369-1378. PubMed ID: 31545507
[TBL] [Abstract][Full Text] [Related]
33. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
Peris K; Licitra L; Ascierto PA; Corvò R; Simonacci M; Picciotto F; Gualdi G; Pellacani G; Santoro A
Future Oncol; 2015; 11(4):703-12. PubMed ID: 25686123
[TBL] [Abstract][Full Text] [Related]
34. Known and new facts on basal cell carcinoma.
Seidl-Philipp M; Frischhut N; Höllweger N; Schmuth M; Nguyen VA
J Dtsch Dermatol Ges; 2021 Jul; 19(7):1021-1041. PubMed ID: 34288482
[TBL] [Abstract][Full Text] [Related]
35. Tolerance of sonidegib after intolerance of vismodegib-Experience in two patients with nevoid basal cell carcinoma syndrome (Gorlin syndrome).
Venturi F; Trane L; Silvestri F; Zuccaro B; Magnaterra E; De Giorgi V
Skin Health Dis; 2023 Oct; 3(5):e260. PubMed ID: 37799353
[TBL] [Abstract][Full Text] [Related]
36. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
[TBL] [Abstract][Full Text] [Related]
37. Nonsurgical treatment options for basal cell carcinoma - focus on advanced disease.
Goldenberg G; Hamid O
J Drugs Dermatol; 2013 Dec; 12(12):1369-78. PubMed ID: 24301238
[TBL] [Abstract][Full Text] [Related]
38. Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.
Mesti T; Sever M; Ocvirk J
Dermatology; 2023; 239(1):158-164. PubMed ID: 35896082
[TBL] [Abstract][Full Text] [Related]
39. Systemic therapy for inoperable and metastatic basal cell cancer.
Fecher LA
Curr Treat Options Oncol; 2013 Jun; 14(2):237-48. PubMed ID: 23558911
[TBL] [Abstract][Full Text] [Related]
40. Topical hedgehog inhibitors for basal cell carcinoma: how far away are we?
Zhu H; Lewis DJ
Expert Opin Pharmacother; 2022 Apr; 23(6):739-740. PubMed ID: 35258366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
